Michael Arzt, MD, investigated the use of ASV therapy in patients with TE-CSA and cardiovascular disease, finding it effective in reducing sleepiness and improving quality of life. It may be more suitable for some patients to be treated with ASV than CPAP due to its ability to automatically adjust pressure and potentially improve comfort.
Preliminary clinical trial results showed the obesity drug tirzepatide was highly effective at treating obstructive sleep apnea, according to information sent to investors of the pharmaceutical company Eli Lilly.